Maria Vinsensia
Overview
Explore the profile of Maria Vinsensia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meixner E, Wermes L, Hoeltgen L, von Diest L, Sandrini E, Harrabi S, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682174
: Definitive radiochemotherapy with concomitant cisplatin 40 mg/m weekly represents the standard of care for locally advanced cervical cancer. Current studies (KEYNOTE-A18 and INTERLACE) are intensifying this regimen at the...
2.
Meixner E, Hoeltgen L, Dinges L, Harrabi S, Seidensaal K, Weykamp F, et al.
Strahlenther Onkol
. 2024 Nov;
PMID: 39531126
Purpose: The appearance of symptomatic tumor-related vaginal bleeding and pain in advanced incurable cancer patients with pelvic gynecological malignancies remains a therapeutic challenge in oncological treatment. The aim of our...
3.
Meixner E, Glogauer B, Kluter S, Wagner F, Neugebauer D, Hoeltgen L, et al.
Clin Transl Radiat Oncol
. 2024 Sep;
49:100855.
PMID: 39308634
Introduction: Target volume delineation is routinely performed in postoperative radiotherapy (RT) for breast cancer patients, but it is a time-consuming process. The aim of the present study was to validate...
4.
Vinsensia M, Schaub R, Meixner E, Hoegen P, Arians N, Forster T, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254756
Methods: We retrospectively analyzed 118 women with breast cancer who underwent PMRT following an IBR between 2010 and 2022. Patients were treated with PMRT of 50.0-50.4 Gy in 25-28 fractions....
5.
Hoeltgen L, Meixner E, Hoegen P, Sandrini E, Weykamp F, Forster T, et al.
Technol Cancer Res Treat
. 2023 Apr;
22:15330338231164537.
PMID: 37038619
Women with locally advanced breast cancer (LABC) or inoperable local recurrence often suffer from a significantly reduced quality of life (QOL) due to local tumor-associated pain, bleeding, exulceration, or malodorous...
6.
Roesch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D, et al.
Radiother Oncol
. 2022 Oct;
181:109380.
PMID: 36273736
Materials And Methods: Patients with locoregionally recurrent or second primary HNSCC undergoing re-irradiation with modern radiotherapy technique were eligible for this multicentric retrospective analysis. Main endpoints were overall survival (OS),...
7.
Bednarova S, Lindenberg M, Vinsensia M, Zuiani C, Choyke P, Turkbey B
Transl Androl Urol
. 2017 Jul;
6(3):413-423.
PMID: 28725583
Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have...
8.
Vinsensia M, Chyoke P, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, et al.
J Nucl Med
. 2017 Jun;
58(12):1949-1955.
PMID: 28637799
Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastases in patients with biochemical relapse of prostate cancer. In this retrospective investigation, the dimensions, volume, localization,...
9.
Kesch C, Vinsensia M, Radtke J, Schlemmer H, Heller M, Ellert E, et al.
J Nucl Med
. 2017 May;
58(11):1805-1810.
PMID: 28473595
Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT represents an advanced method for the staging of primary prostate cancer (PCa) and diagnosis of recurrent or metastatic PCa. However, because of the narrow availability...